Clomiphene

• Ovulation Induction
• Polycystic Ovary Syndrome (PCOS)
• Female Infertility
• Anovulatory Infertility

Clomiphene citrate (Clomid, Serophene) is an oral selective estrogen receptor modulator (SERM) used to induce ovulation in women whose infertility stems from anovulation, most commonly polycystic ovary syndrome (PCOS) or hypothalamic dysfunction. It has been a first-line ovulation induction agent for over five decades because it is taken by mouth, well tolerated, inexpensive, and effective in restoring ovulatory cycles in roughly 70-80% of appropriately selected patients. Pregnancy rates per ovulatory cycle hover around 15-20%, with cumulative pregnancy rates approaching 40-60% over six cycles in women without other infertility factors. Clomiphene is also used off-label in male hypogonadism to stimulate endogenous testosterone production, an option that preserves fertility in contrast to exogenous testosterone replacement.

Mechanism of Action

Clomiphene is a nonsteroidal mixture of two geometric isomers — zuclomiphene (the more estrogenic, longer-acting isomer) and enclomiphene (the more anti-estrogenic, shorter-acting isomer) — that act as competitive estrogen receptor antagonists at the hypothalamus. By blocking hypothalamic estrogen receptors, clomiphene removes the normal negative feedback signal that estradiol provides, causing the hypothalamus to perceive an estrogen-deficient state. The hypothalamus responds with increased pulsatile gonadotropin-releasing hormone (GnRH) secretion, which stimulates the anterior pituitary to release more follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Elevated FSH drives ovarian follicular recruitment and growth, and a rising estradiol level eventually triggers an LH surge and ovulation, typically 5-12 days after the last clomiphene tablet. Anti-estrogenic effects on the cervix and endometrium are clomiphene's main downsides — thicker cervical mucus and a thinner endometrial lining can blunt the fertility benefit even when ovulation is restored. The relatively long half-life of zuclomiphene (about two weeks) explains why anti-estrogenic effects can persist beyond the five-day dosing window. In men used off-label, the same hypothalamic-pituitary unblocking raises endogenous LH, which stimulates testicular Leydig cells to produce testosterone while preserving spermatogenesis.

Clinical Use

Clomiphene is the traditional first-line treatment for ovulation induction in women with PCOS, although letrozole has overtaken it as the preferred agent in PCOS based on the PPCOS II trial and current American Society for Reproductive Medicine guidance, demonstrating higher live-birth rates and lower multiple-pregnancy risk. Clomiphene remains useful for hypothalamic anovulation, unexplained infertility (often combined with intrauterine insemination), and as an off-label option for male secondary hypogonadism and luteal-phase support. It is not effective for women with primary ovarian insufficiency, hyperprolactinemia, or thyroid disorders — those underlying causes (such as hyperthyroidism or hypothyroidism) need to be corrected first. A pre-treatment workup typically includes a documented anovulatory pattern, a normal uterine cavity and at least one patent fallopian tube confirmed by hysterosalpingogram, a recent semen analysis from the male partner, confirmation of a normal TSH, prolactin, and androgen panel, and a discussion of weight, sleep, and exercise. In PCOS, even modest weight loss of 5-10% can restore ovulation without medication, so metformin and lifestyle interventions are commonly offered alongside or before clomiphene. Patients with PCOS often have insulin resistance and an elevated long-term cardiometabolic risk that deserves attention beyond the immediate fertility goal — see our discussion of understanding metabolic syndrome.

How to Take It

Clomiphene is taken as a 50 mg tablet once daily for five consecutive days, traditionally starting on cycle day 3, 4, or 5 (counting the first day of full menstrual flow as day 1). Take the tablet at the same time each day, with or without food. Ovulation is expected 5 to 12 days after the last tablet, so timed intercourse every other day from cycle day 10 through cycle day 20 maximizes the chance of conception. Some couples choose to use ovulation predictor kits beginning around cycle day 10 to identify the LH surge and time intercourse more precisely. If a dose is missed, take it as soon as you remember unless the next dose is due within a few hours; do not double up, and contact your clinician if you miss more than one dose during the five-day window — the cycle may need to be canceled and restarted. Most clinicians complete a pregnancy test before each new cycle to avoid inadvertent dosing during early pregnancy, since clomiphene is teratogenic. Common first-week effects include hot flashes, mood swings, mild bloating, breast tenderness, and headaches; these usually resolve within days of completing the five-day course. Visual symptoms (blurring, flashing lights, scotomata) are uncommon but require stopping the medication and prompt evaluation, as they may persist or progress. Avoid alcohol the week of dosing if it worsens vasomotor symptoms.

Monitoring and Follow-Up

Ovulation can be confirmed by mid-luteal (cycle day 21) progesterone level, basal body temperature charting, ovulation predictor kits, or transvaginal ultrasound follicular monitoring. A progesterone level above 3 ng/mL confirms ovulation, with levels above 10 ng/mL suggesting a robust luteal phase. If ovulation does not occur on 50 mg, the dose is increased to 100 mg in the next cycle, and occasionally to 150 mg, although response above 100 mg is uncommon. Most clinicians do not exceed six ovulatory cycles before moving to letrozole, gonadotropins, or assisted reproductive technology, because the marginal benefit of additional clomiphene cycles falls off sharply. Baseline labs typically include a comprehensive metabolic panel and CBC, TSH, prolactin, total and free testosterone, DHEA-S, and 17-hydroxyprogesterone if PCOS is suspected. Persistent ovarian cysts on early-cycle ultrasound delay the next cycle. Couples should set realistic expectations — even with successful ovulation, monthly conception rates are limited by partner factors, age, and tubal status, and a structured timeline with predefined transition points to advanced therapies prevents prolonged frustration.

Special Populations

Clomiphene is contraindicated in pregnancy (a careful menstrual history and pregnancy test before each cycle are essential), active liver disease, undiagnosed abnormal uterine bleeding, hormone-sensitive tumors, ovarian cysts other than functional cysts in PCOS, and uncontrolled thyroid or adrenal dysfunction. It is not used during lactation. Women over 38 generally have lower success rates and may benefit from earlier referral to reproductive endocrinology rather than prolonged trials of clomiphene, given the accelerating decline in ovarian reserve. Patients with PCOS often have coexisting insulin resistance and may benefit from concurrent metformin and lifestyle change. Men using clomiphene off-label for hypogonadism need baseline and follow-up testosterone, LH, FSH, hematocrit, and prostate-specific antigen monitoring. Smoking, obesity, and uncontrolled diabetes all reduce the chance of successful conception and are addressed before or alongside ovulation induction.

When to Contact Your Doctor

Seek urgent care for severe pelvic or abdominal pain, rapid abdominal swelling, shortness of breath, decreased urination, sudden weight gain of several pounds in 24 hours, or persistent nausea and vomiting — these can signal ovarian hyperstimulation syndrome, which although rare with clomiphene can be serious. Stop the medication and call your clinician for any visual disturbance (blurring, double vision, flashes, dark spots), severe headache that does not respond to acetaminophen, or signs of pregnancy such as a missed expected period and positive pregnancy test. Severe mood changes, depression, or thoughts of self-harm warrant prompt mental health attention.

When clomiphene cycles do not lead to pregnancy, the next steps depend on age, tubal status, semen parameters, and patient preference. Options include switching to letrozole, adding intrauterine insemination, advancing to injectable gonadotropins (which carry higher cost and higher multiple-pregnancy risk and require frequent monitoring), or proceeding to in vitro fertilization. Some patients benefit from referral to a reproductive endocrinology specialist when standard ovulation induction is not yielding results. The emotional toll of fertility treatment is significant, and integrating mental health support, peer connection, and clear communication with a partner is part of comprehensive care. For a deeper look at hormone-related health, our article on thriving after menopause addresses what comes later in the reproductive arc and underscores why thoughtful management of hormonal health across the lifespan matters. Patients who conceive while on clomiphene should know that there is no evidence of increased risk of congenital anomalies in pregnancies conceived shortly after a clomiphene cycle, and routine prenatal care follows standard guidelines.

For a full fertility evaluation, baseline labs, individualized counseling about clomiphene versus letrozole, and a structured plan with realistic timelines, contact us or schedule a visit at Zimmer Medical Group.